Screening for colorectal cancer(CRC)is among the mosteffective approaches to cancer prevention,yet achievinghigh adherence to effective screening offers is challenging[1].Blood-based tests that could be easily impleme...Screening for colorectal cancer(CRC)is among the mosteffective approaches to cancer prevention,yet achievinghigh adherence to effective screening offers is challenging[1].Blood-based tests that could be easily implemented inroutine medical practice might be a promising approachto achieve higher adherence rates than with conven-tional stool-based or endoscopic screening[2,3].However,neoplasm detection rates of previously developed and pro-posed blood-based tests have not been competitive tothose of modern stool-based tests[2],in particular fecalimmunochemical tests(FITs)that are meanwhile widelyused for CRC screening in an increasing number of coun-tries[4].Most recently,performance of a novel cell-freeDNA(cfDNA)blood-based test for detecting colorectalneoplasms was validated in the ECLIPSE study,a largescreening population undergoing screening colonoscopy[5],being the first of its kind to achieve FDA approval asa primary screening option for CRC.展开更多
基金funded by grants from the GermanResearch Council(DFG,grant No.BR1704/16-1)the Fed-eral Ministry of Education and Research(BMBF,grantno.01GL1712 and 01KD2104A)the German CancerAid(No.70113330).
文摘Screening for colorectal cancer(CRC)is among the mosteffective approaches to cancer prevention,yet achievinghigh adherence to effective screening offers is challenging[1].Blood-based tests that could be easily implemented inroutine medical practice might be a promising approachto achieve higher adherence rates than with conven-tional stool-based or endoscopic screening[2,3].However,neoplasm detection rates of previously developed and pro-posed blood-based tests have not been competitive tothose of modern stool-based tests[2],in particular fecalimmunochemical tests(FITs)that are meanwhile widelyused for CRC screening in an increasing number of coun-tries[4].Most recently,performance of a novel cell-freeDNA(cfDNA)blood-based test for detecting colorectalneoplasms was validated in the ECLIPSE study,a largescreening population undergoing screening colonoscopy[5],being the first of its kind to achieve FDA approval asa primary screening option for CRC.
